Publications by authors named "Qiuhong Yong"
Background: Non-alcoholic steatohepatitis (NASH) and liver fibrosis are progressive conditions associated with non-alcoholic fatty liver disease (NAFLD), characterized by hepatocyte pyroptosis and hepatic stellate cell (HSC) activation. Gentiopicroside (GPS) has emerged as a potential treatment for NASH, yet its underlying mechanism remains unclear.
Aim: To confirm that GPS can improve NASH and liver fibrosis by blocking the NLRP3 signaling pathway STUDY DESIGN: Initially, different animal models were used to study the effects and mechanisms of GPS on NASH and fibrosis.
Article Synopsis
- MASLD (Metabolic dysfunction-associated steatotic liver disease) is on the rise due to obesity and lifestyle changes, prompting research into the therapeutic effects of ursolic acid, a natural compound.
- The study utilized various methods, including drug target chips and molecular docking, to explore ursolic acid's effects on MASLD and validated findings using animal models and isolated CD4+ T cells.
- Results showed that ursolic acid inhibits the inflammatory role of the protein SPP1 in Th17 cell differentiation, modulating immune responses through the ERK signaling pathway, highlighting its potential as a treatment for MASLD.
Gentiopicroside (GPS) is a highly water-soluble small-molecule drug and the main bioactive secoiridoid glycoside of Gentiana scabra that has been shown to have hepatoprotective effects against non-alcoholic steatohepatitis (NASH), a form of non-alcoholic fatty liver disease (NAFLD) that can progress to cirrhosis and hepatocellular carcinoma. However, the effects of GPS on NASH and the underlying mechanisms remain obscure. Firstly, a high-fat, high-cholesterol (HFHC) diet and a high-sugar solution containing d-fructose and d-glucose were used to establish a non-alcoholic steatohepatitis (NASH) mice model.
View Article and Find Full Text PDF